Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. (Nasdaq: EDIT) is a clinical-stage genome editing company committed to developing transformative genomic medicines to treat serious diseases. The company leverages its proprietary CRISPR/Cas9 and CRISPR/Cas12a technology to create precise and corrective molecular modifications at the genetic level, aiming to address the root cause of various diseases. Editas Medicine has made significant strides in the development and commercialization of its genome editing platform. Currently, the company is advancing its flagship program, EDIT-301, now known as renizgamglogene autogedtemcel (reni-cel), which shows promise as a one-time, durable treatment for severe sickle cell disease (SCD) and beta thalassemia (TDT). Recent data from the RUBY and EdiTHAL trials indicate that reni-cel is well-tolerated and has demonstrated significant clinical benefits, including early correction of anemia and sustained increases in fetal hemoglobin.
Financially, Editas Medicine maintains a strong position, with cash, cash equivalents, and marketable securities amounting to $446.4 million as of September 30, 2023. The company's financial strategy is bolstered by strategic partnerships such as the recent license agreement with Vertex Pharmaceuticals and an extended collaboration with Bristol Myers Squibb. These agreements extend Editas Medicine's cash runway into 2026, supporting ongoing and future projects.
Editas Medicine is also pioneering in vivo genome editing. Recent preclinical data presented at the American Society of Gene and Cell Therapy (ASGCT) meeting showcased the company's progress in lipid nanoparticle (LNP) formulations for efficient in vivo delivery of AsCas12a mRNA, demonstrating significant scientific advancements in the field.
The company's mission is reinforced by its strong intellectual property portfolio, including exclusive licenses for CRISPR/Cas12a and CRISPR/Cas9 genome editing systems from Broad Institute and Harvard University. The company remains dedicated to translating groundbreaking genomic research into clinical applications, aiming to provide life-changing therapies for patients worldwide.
For the latest updates, including financial results, clinical trial progress, and strategic initiatives, visit the Editas Medicine website.
Editas Medicine, Inc. (Nasdaq: EDIT) announced that the U.S. Patent and Trademark Office has granted Broad Institute’s motion for priority in a patent interference case. This decision denies priority to CVC, meaning Broad is now the 'Senior Party.' Editas remains confident in its exclusive licenses for foundational CRISPR/Cas9 patents. Broad’s patents are valid in multiple jurisdictions, including the U.S., and Editas aims to leverage these innovations in developing treatments for serious diseases.
Editas Medicine, a leading genome editing company, will participate in several upcoming investor conferences. Key events include Citi’s 15th Annual BioPharma Virtual Conference on September 9, 2020, at 3:20 p.m. ET, a fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference on September 10, 2020, at 10:40 a.m. ET, and another fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 10:15 a.m. ET. These events will be webcast live on the company’s website, with recordings available for 30 days afterwards.
Editas Medicine has regained full control of ocular medicines with a new agreement with AbbVie. The company is on track to dose patients in the BRILLIANCE trial for EDIT-101 by the end of 2020, and plans to file an IND for EDIT-301 for sickle cell disease. A recent equity offering raised $216 million, strengthening its balance sheet, which now holds $599 million in cash as of June 30, 2020. The company reported a net loss of $23.6 million for Q2 2020, an improvement from $33.8 million in Q2 2019, with an increase in collaboration revenues to $10.7 million.
Editas Medicine has regained full global rights to develop and commercialize ocular medicines, including EDIT-101 for Leber congenital amaurosis 10, after terminating a previous alliance with Allergan, now part of AbbVie. CEO Cynthia Collins expressed optimism about advancing EDIT-101, with dosing resuming in the Phase 1/2 BRILLIANCE trial. They aim to complete dosing of the adult low-dose cohort and dose adult mid-dose patients by year-end. J.P. Morgan Securities LLC is advising Editas on this transition.
Editas Medicine (Nasdaq: EDIT) has partnered with Catalent to enhance the development and manufacturing of its in vivo CRISPR medicines and engineered cell therapies. Catalent will support Editas with clinical supply and production from its facilities in Maryland and Texas, ensuring efficient delivery to clinical trial sites. This collaboration aims to leverage Catalent's advanced technologies to expedite Editas' innovative therapies, potentially improving patient access to new treatments.
Editas Medicine has appointed Gad Berdugo as the new Chief Business Officer, effective immediately. Berdugo brings over 25 years of experience in biotech corporate development and business strategy. He previously held executive roles at EpiVax Oncology and Immune Pharmaceuticals. Under his leadership, Editas aims to enhance its business development and advance its clinical and preclinical pipeline, which includes ongoing trials and strategic partnerships. President Cynthia Collins expressed confidence in Berdugo's ability to drive the company’s growth amidst the dynamic gene editing landscape.
Editas Medicine, a leader in genome editing, will host a conference call on August 6, 2020, at 5:00 p.m. ET to discuss its corporate updates and Q2 2020 results. Participants can join the call by dialing 844-348-3801 (domestic) or 213-358-0955 (international) and using passcode 9185596. A live webcast will also be available on their website. Editas focuses on leveraging CRISPR technology to develop transformative genomic treatments for serious diseases worldwide.
On June 26, 2020, Editas Medicine (Nasdaq: EDIT) announced the completion of its underwritten public offering, selling 6,900,000 shares of common stock at a price of $31.25 per share. The offering generated approximately $215.6 million in gross proceeds, which includes 900,000 shares sold due to underwriter options. The registration statement related to the offering has been filed and is effective with the SEC. Morgan Stanley acted as the sole book-running manager for this offering.
Editas Medicine has announced an underwritten offering of 6,000,000 shares of its common stock at a price of $31.25 per share, aiming for gross proceeds of approximately $187.5 million. The offering features a 30-day option for underwriters to purchase an additional 900,000 shares. Scheduled to close around June 26, 2020, this transaction is being managed by Morgan Stanley and follows a Form S-3 registration with the SEC.
Editas Medicine (Nasdaq: EDIT) announced plans to offer 4,000,000 shares of common stock in a public offering, with the potential to sell an additional 600,000 shares. The offering will be managed by Morgan Stanley and is subject to market conditions. A registration statement has been filed with the SEC, and the offering details will be available through the final prospectus. Editas aims to utilize the funds to advance its CRISPR-based therapeutic pipeline targeting serious diseases. The offering carries uncertainties regarding completion and final terms.
FAQ
What is the current stock price of Editas Medicine (EDIT)?
What is the market cap of Editas Medicine (EDIT)?
What is the primary focus of Editas Medicine?
What is EDIT-301?
How is Editas Medicine performing financially?
Who are Editas Medicine's key partners?
What recent achievements has Editas Medicine made?
What are the RUBY and EdiTHAL trials?
What is Editas Medicine's approach to in vivo genome editing?
What is Editas Medicine's intellectual property strategy?
How can I stay updated on Editas Medicine's progress?
When are Editas Medicine's next investor events?
